Conclusion : Terlipressin improved the clinical syndromes and prognosis of patients with hepatorenal syndrome ( HRS ) reduced the level of blood creatinine increased the urine volume . Terlipressin will provid us a new way to treat patients with hepatorenal syndrome ( HRS ) .

结论： 特利 加压 素 治疗肝肾综合征可改善患者临床症状及预后，降低血肌酐水平，增加尿量，为治疗该病提供新的措施。

Results 6h after the administer of Terlipressin patients ' MAP rose and shock index number reduced dramatically 12h after treatment by Terlipressin patients ' HR improved significantly ( P0.01 ) .

结果 特利 加压 素 使用6h后 平均 动脉压 明显上升、休克指数明显下降，使用12h后心率、尿 量明显改善。

Effects of terlipressin and pituitrin on portal hemodynamics in rabbits with prehepatic portal hypertension

特利 加压 素、垂体后叶素对正常及门脉高压兔门脉血流动力学影响的研究

Results Success of therapy in terlipressin group ( 80.5 % ) was similar to that in stilamin group ( 83.7 % ) .

结果 特利 加压 素组治疗有效率（805%）类似于施他宁组（837%）；

Conclusions Perioperative terlipressin-based comprehensive treatment can effectively improve renal function to promote survival rate in patients with HRS .

结论对 肝 移植围手术期的HRS病人采用 terlipressin 结合 CRRT及 2剂 赛尼 哌 诱导疗法的综合治疗可以明显改善病人的肾功能，提高生存率。

Protective strategy of Terlipressin on the remnant livers after major hepatectomy in rats residual expansion of tank volume

特利 加压 素对肝大部切除术后大鼠小体积残肝的保护性治疗罐体容积残余变形值

Effect observe of terlipressin on hepatorenal syndrome

特利 加压 素 治疗肝肾综合征的疗效观察

However 60 minutes after injection the roles of pituitrin vanished but terlipressin still had significant effects ( P 0.05 ) .

但注射药物后60min，垂体后叶素的作用 基本消失，而 特利 加压 素仍有明显的 降压作用（P0.05）。

Conclusion Terlipressin have clinical therapeutic effects for intractable septic shock .

结论对 严重脓毒血症难治性休克， 特利 加压 素具有 一定的临床 应用 价值。

Objective To evaluate the clinical efficacy of Terlipressin for treatment of intractable septic shock .

目的旨在探讨 特利 加压 素 （ Terlipressin ）对脓毒血症难治性休克的临床应用 价值。